

Tom Le Voyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2696684/publications.pdf>

Version: 2024-02-01

17
papers

3,405
citations

687363

13
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

6961
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <i>Science Immunology</i> , 2023, 8, .	11.9	35
2	Human genetic and immunological determinants of critical COVID-19 pneumonia. <i>Nature</i> , 2022, 603, 587-598.	27.8	216
3	Pulmonary Alveolar Proteinosis and Multiple Infectious Diseases in a Child with Autosomal Recessive Complete IRF8 Deficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 975-985.	3.8	7
4	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	7.1	110
5	Chronic Granulomatous Disease-Like Presentation of a Child with Autosomal Recessive PKC ζ Deficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 1244-1253.	3.8	6
6	Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. <i>Journal of Clinical Immunology</i> , 2021, 41, 639-657.	3.8	30
7	JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. <i>Rheumatology</i> , 2021, 60, 5801-5808.	1.9	52
8	Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	130
9	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	185
10	Genetic, Immunological, and Clinical Features of 32 Patients with Autosomal Recessive STAT1 Deficiency. <i>Journal of Immunology</i> , 2021, 207, 133-152.	0.8	33
11	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	11.9	357
12	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	267
13	Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. <i>Science Translational Medicine</i> , 2021, 13, eabh2624.	12.4	155
14	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	12.6	1,749
15	Autosomal recessive complete STAT1 deficiency caused by compound heterozygous intronic mutations. <i>International Immunology</i> , 2020, 32, 663-671.	4.0	26
16	Mendelian Susceptibility to Mycobacterial Disease Caused by a Novel Founder IL12B Mutation in Saudi Arabia. <i>Journal of Clinical Immunology</i> , 2018, 38, 278-282.	3.8	9
17	Impaired IL-12- and IL-23-Mediated Immunity Due to IL-12R β 1 Deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease. <i>Journal of Clinical Immunology</i> , 2018, 38, 787-793.	3.8	13